Novo Nordisk Partners with Emcure to Launch New Weight-Loss Drug Brand ‘Poviztra’ in India
Novo Nordisk has announced an exclusive partnership with Emcure Pharmaceuticals to distribute and market its new weight-loss drug brand, Poviztra, in India. The Danish pharmaceutical giant will introduce Poviztra as a 2.4 mg semaglutide injection, representing a separate brand of its globally successful treatment, Wegovy. This strategic collaboration aims to enhance accessibility and expand the reach of Novo Nordisk’s innovative therapies to a broader patient base across the country.
The partnership announcement triggered a market response, with Emcure Pharma’s shares surging 6.5% to ₹1,451. Novo Nordisk had previously launched Wegovy in India in June, shortly after U.S.-based Eli Lilly introduced its rival weight-loss treatment, Mounjaro. Wegovy’s 2.4 mg dose currently retails at ₹26,015 for a month’s supply, though pricing details for Poviztra have not yet been disclosed.
This collaboration mirrors a growing trend among global pharmaceutical leaders forming alliances with Indian drugmakers to capture the rapidly expanding obesity and wellness treatment market. Eli Lilly recently entered a similar partnership with Cipla to sell its weight-loss drug under a separate brand in India, further intensifying competition in the country’s high-potential metabolic health segment.
Pic Courtesy: google/ images are subject to copyright
